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Superoxide dismutase 1 (SOD1) is an abundant copper/zinc enzyme
found in the cytoplasm that converts superoxide into hydrogen
peroxide and molecular oxygen. Tetrathiomolybdate (ATN-224)
has been recently identified as an inhibitor of SOD1 that attenuates
FGF-2- and VEGF-mediated phosphorylation of ERK1/2 in endothe-
lial cells. However, the mechanism for this inhibition was not
elucidated. Growth factor (GF) signaling elicits an increase in
reactive oxygen species (ROS), which inactivates protein tyrosine
phosphatases (PTP) by oxidizing an essential cysteine residue in the
active site. ATN-224-mediated inhibition of SOD1 in tumor and
endothelial cells prevents the formation of sufficiently high levels
of H2O2, resulting in the protection of PTPs from H2O2-mediated
oxidation. This, in turn, leads to the inhibition of EGF-, IGF-1-, and
FGF-2-mediated phosphorylation of ERK1/2. Pretreatment with
exogenous H2O2 or with the phosphatase inhibitor vanadate
abrogates the inhibition of ERK1/2 phosphorylation induced by
ATN-224 or SOD1 siRNA treatments. Furthermore, ATN-224-
mediated SOD1 inhibition causes the down-regulation of the PDGF
receptor. SOD1 inhibition also increases the steady-state levels of
superoxide, which induces protein oxidation in A431 cells but,
surprisingly, does not oxidize phosphatases. Thus, SOD1 inhibition
in A431 tumor cells results in both prooxidant effects caused by the
increase in the levels of superoxide and antioxidant effects caused
by lowering the levels of H2O2. These results identify SOD1 as a
master regulator of GF signaling and as a therapeutic target for the
inhibition of angiogenesis and tumor growth.
angiogenesis  cancer  redox  tetrathiomolybdate  ATN-224
Tetrathiomolybdate (TM) is a copper-binding drug that has beenshown to have efficacy as an anti-angiogenic and anti-tumor
agent in several mouse models of cancer (1–8) and has been tested
in several oncology clinical trials (9–11). ATN-224 is a second-
generation analogue of TM, which is currently being evaluated in
several phase II trials in cancer patients (11). The copper dependent
enzyme superoxide dismutase 1 (SOD1) has recently been identi-
fied as the main target for the anti-angiogenic activity of ATN-224
(1). SOD1 belongs to the SOD family of enzymes, which catalyze
the dismutation of superoxide into H2O2 and oxygen, thus main-
taining low steady-state levels of superoxide (1010 M) (12–14).
Because excess superoxide is toxic and superoxide has very poor
membrane permeability, SOD is ubiquitously present in different
organelles within the cell (12). SOD1 is present in the cytosol,
nucleus and the intermembrane space of mitochondria; SOD2, a
manganese containing enzyme, is present in the mitochondrial
matrix, and ecSOD (SOD3), a secreted copper containing protein,
is found in the extracellular matrix of tissues (12). The SOD family
of enzymes has been extensively studied. Although the SOD2
knock-out is lethal in mice (15), the SOD1 and ecSOD knock out
phenotypes are generally considered mild (16–20). CuZnSOD
(SOD1) knock out mice are usually healthy although female mice
may have decreased fertility (17). More recently, SOD1/ mice
were found to have an elevated susceptibility to liver tumors (18) as
a consequence of a high rate of DNA mutations that occur at an
early age (2–6months) (19). SOD1knock-down by siRNAhas been
shown to induce senescence in fibroblasts (21).
We showed that ATN-224 inhibits proliferation in human um-
bilical vein endothelial cells (HUVEC) and induces apoptosis in
MM1S multiple myeloma tumor cells (1). SOD1 inhibition by
ATN-224 increased the steady-state levels of superoxide in
HUVEC (1). Furthermore, ATN-224 treatment of HUVEC abol-
ished FGF-2 and VEGF-mediated ERK1/2 phosphorylation (1).
We hypothesized that the inhibition of ERK phosphorylation was
due to an imbalance in ROS, which have been known to affect
multiple signaling pathways (22–26). However, the precise mech-
anism bywhich inhibition of SOD1 abolishes ERKphosphorylation
was not determined. Signaling regulation byROS generally involves
the reversible oxidation of Cys residues in target proteins leading to
subsequent alteration of activity (22–26). The activity of several
growth factors (GF) e.g., EGF, IGF-1, PDGF, and VEGF is redox
regulated by a mechanism in which GF binding to its receptor
tyrosine kinase activates production of ROS, which in turn inacti-
vates phosphatases, shifting the balance within cells toward phos-
phorylation and allowing kinase cascades to propagate (22–26). All
protein tyrosine phosphatases (PTPs) have an essential cysteine
(Cys) residue in their active sites that is readily oxidized because of
a lower pKa than normally found for the Cys thiol (23, 24). The
source and nature of theROS involved in this process are not clearly
defined; however, it is suspected that either superoxide or H2O2,
produced by superoxide dismutation, or both oxidize PTPs.
Here, we present evidence showing that SOD1 is essential for
growth factor signaling in endothelial and tumor cells. Inhibition of
SOD1 protects PTPs from oxidation by preventing the formation
of H2O2. This, in turn, inhibits ERK phosphorylation in cells
stimulated with EGF, FGF-2, or IGF-1. Paradoxically, SOD1
inhibition induces both prooxidant effects mediated by an excess
superoxide and antioxidant effects caused by a decrease in H2O2.
These results further validate SOD1 as a therapeutic target for the
inhibition of angiogenesis and tumor growth.
Results
SOD1 Is the Target for ATN-224, and Its Inhibition Attenuates EGF- and
IGF-1-Mediated ERK1/2 Phosphorylation in Cells. The effects of ATN-
224 on SOD1 inhibition, proliferation, and signaling in HUVEC
and MM1S cells have been demonstrated to be maximal after 48 h
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of incubation (1). Thus, the standard treatment of cells with
ATN-224 in signaling studies is for 48 h in full growth media. The
IC50 for ATN-224 inhibition of SOD1 in A431 cells was 185  65
nM (n 5), and, for the inhibition of proliferation, it was 4.5 0.40
M (n  6) (Fig. 1A), indicating that SOD1 must be completely
inhibited to achieve antiproliferative effects as has already been
shown for HUVEC (1). As expected, SOD1 siRNA did not have
antiproliferative effects by itself, because it did not inhibit SOD1
activity completely (70% inhibition). However, it had additive
effects with ATN-224 (Fig. 1B). As shown for HUVEC (1), the
SOD mimetic Mn(III)tetrakis(4-benzoic acid) porphyrin (MnT-
BAP) abrogated the antiproliferative effects of ATN-224 in A431
cells (Fig. 1C). Altogether, these results (Fig. 1 B and C) confirm
that SOD1 is the target of ATN-224’s antiproliferative activity.
Because ATN-224 treatment of HUVEC abolished FGF-2, and
VEGF mediated ERK1/2 phosphorylation (1), we evaluated
whether ATN-224 treatment would inhibit ERK1/2 phosphoryla-
tion in tumor cells. We chose GF that are known to be redox
regulated, such as EGF and IGF-1 (22, 23, 25, 27), and cell lines
known to be sensitive to the particular GF. ATN-224 treatment
decreased phosphorylation of ERK1/2 (pERK) mediated by EGF
in A431, but not in A549 cells (Fig. 1D). ATN-224 treatment at the
concentrations used in this study completely inhibits SOD activity
in all cell types evaluated (data not shown). Supporting information
(SI) Fig. S1A shows decreases in pERK with increasing concen-
trations of ATN-224 in EGF-stimulated A431 cells. ATN-224
treatment also inhibited pERK in HT-29 cells stimulated with
IGF-1 (Fig. 1E) and triggered apoptosis in both A431 and HT-29
(Fig. S1B). Some tumor cells, such as A549 cells, were resistant to
ATN-224-mediated inhibition of pERK (Fig. 1D), and apoptosis
was not induced in these cells. However, ATN-224 treatment did
inhibit proliferation in these cells (data not shown). If the signaling
effects mediated by ATN-224 were due to the inhibition of SOD1,
then SOD1 siRNA should replicate the results. Treatment with
SOD1 siRNAs, but not control siRNA, attenuated ERK1/2 phos-
phorylation inA431 cells stimulated with EGF (Fig. 1F), suggesting
thatATN-224 effects on signaling are the result of SOD1 inhibition.
ATN-224-mediated inhibition of pERK was also observed in IGF-
1-inducedMM1S or EGF-stimulated fibroblasts (HDFa) (Fig. S1C
and D). Furthermore, ATN-224 also inhibited the high basal levels
of pERK in U87 glioblastoma cells (Fig. S1E). Therefore, inter-
ference with SOD1 has antiproliferative/antiproapoptotic activity
and inhibits EGF and IGF-1 stimulation of pERK in several cell
lines in vitro.
SOD1 Inhibition Attenuates Phosphorylation of the EGF Receptor
(EGFR) and the IGF-1 Receptor (IGF-1R) and Down-Regulates the
PDGF Receptor (PDGFR). To investigate at which level the inhibition
of theMAPKpathway was taking place, the phosphorylation of the
EGFR at Tyr 1173 and of IGF-1R at Tyr-1135/1136 were examined
after ATN-224 treatment in EGF or IGF-1-treated cells. Maximal
phosphorylation of the receptors occurred at 100 ng/ml for EGF
and 20 ng/ml for IGF-1. Phosphorylation of theEGFR(Fig. 2A and
B) and IGF-1R (Fig. 2C) after stimulation with EGF and IGF-1,
respectively, were decreased by ATN-224 treatment. Furthermore,
ATN-224 treatment of A431 cells attenuated EGF-mediated phos-
phorylation of a subset of Tyr residues (992, 1045, 1068, and 1173)
in the EGFR (Fig. 2B), some of which have been known tomediate
signaling in the MAPK pathway (28) and to be activated by ROS
(29). These results suggest that the down-regulation of pERK
through SOD1 inhibition occurs at the level of the receptor tyrosine
kinase, although other points of inhibition in the cascade cannot be
ruled out. The PDGF pathway is also known to be regulated by
ROS (30, 31). The possible effects of ATN-224 on PDGF signaling
were investigated in U87 glioblastoma cells, which overexpress the
PDGF receptor (PDGFR). ATN-224 treatment of U87 cells
caused the down-regulation of PDGFR protein expression but not
of the EGFR protein (Fig. 2D), indicating the potential for signif-
Fig. 1. SOD1 is the target for ATN-224 and SOD1 inhibition attenuated the phosphorylation of ERK1/2 upon GF stimulation. (A) A431 cells were treated with
ATN-224 for 48 h, and proliferation (MTT assay) (inverted filled triangles) and SOD1 activity (filled circles) were determined. (B) A431 cells were transfected with
SOD1 siRNA (74) (filled circles), control siRNA (inverted filled triangles), or nontransfected (open circles) and plated on a 96-well plate, and proliferation was
determined as inA. (C) A431 proliferation (MTT assay) was measured in cells treated with MnTBAP either alone (filled bars) or with 30M ATN-224 (empty bars).
(D) A431 or A549 cells were treated with ATN-224 for 48 h. Then, cells were stimulated with 10 ng/ml of EGF for 10 min and lysed, and Western blot analyses
were carried out. (E) HT-29 cells were incubated with ATN-224 for 48 h. Then, cells were stimulated with IGF-1 for 10 min and lysed, and ELISAs were carried out.
(F) A431 cells were transfected with different SOD1 siRNA [74, 75, 76, and all three (comb.)] or control siRNA (C) for 48 h. Then, the cells were stimulated with
10 ng/ml of EGF for 10 min and lysed, and Western blot analyses were carried out.
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icant downstream inhibitory effects. In summary, SOD1 inhibition
by ATN-224 results in the attenuation of the EGF and IGF-1
pathways and a considerable decrease in PDGFR protein, which
may have implications for tumor cell growth and survival.
SOD1 Inhibition Increases the Steady-State Levels of Superoxide
Inducing Prooxidant Effects.We then investigated themechanism by
which SOD1 inactivation leads to inhibition of theMAPKpathway,
using primarily A431 cells  EGF. HUVEC  FGF-2 were also
used in some experiments as a model of a primary cell line. Similar
to what we reported for HUVEC (1), 10 M ATN-224 treatment
of A431 cells for 48 h increased the steady-state levels of superoxide
(48  8.5%), as determined by using the superoxide-sensitive
fluorescence dye dihydroethidium (DHE) (Fig. 3A). To confirm
this increase, aconitase activity was measured. Levels of aconitase
activity have been used as an indirect measurement of superoxide
concentration, because superoxide inactivates the [4Fe-4S] cluster
of aconitase (32). The activity of cytosolic aconitase was inhibited
in ATN-224-treated A431 and HUVEC (Fig. 3B), in agreement
with the observed increase in superoxide shown in Fig. 2A and ref.
1. ATN-224 treatment of A431 cells also increased the levels of
protein carbonylation when compared with control cells (Fig. S2),
as would be expected if superoxide levels are higher than normal.
SOD1 Inhibition Decreases the Levels of H2O2, Which Attenuates pERK
in GF-Stimulated Cells. Because the steady-state levels of superoxide
increase on ATN-224 inhibition of SOD1, the levels of H2O2 may
correspondingly decrease. In turn, reducedH2O2 levels could result
in the attenuation of GF signaling by preventing the oxidation and
inactivation of PTPs. The oxidation of dichlorofluorescein
(H2DCFDA) to the highly fluorescent 2,7-dichlorofluorescein
(DCF) is a commonly usedmethod tomeasureH2O2 levels (33–34).
Using H2DCFDA, we determined that the basal levels of H2O2
decreased by 28% (n  3, P  0.012) in ATN-224 (5 M)-treated
A431 cells. To corroborate that ATN-224-mediated inhibition of
SOD1 was lowering the levels of H2O2, we used an indirect
approach. If the observed effects of ATN-224 in signaling are
mediated by a decrease in hydrogen peroxide, adding exogenous
H2O2 to ATN-224-treated cells should reverse the ATN-224-
mediated effects on signaling. Thus, the effects of combined SOD1
inhibition and H2O2 treatment on GF-stimulated ERK/12 phos-
phorylation in HUVEC and A431 cells were evaluated. Treatment
of A431 cells for 48 h with ATN-224 (7 M) decreased the level of
EGF-induced pERK by 87% (Fig. 3C), consistent with the data
presented in Fig. 1D. However, whenH2O2 (1, 10, and 100M)was
added to ATN-224 (7 M)-treated A431 cells 0.5 h before stimu-
lation with EGF, the inhibition of ERK phosphorylation was
decreased to 75.9, 73.2, and 41.3%, respectively, suggesting that the
addition of H2O2 treatment was able to reverse the effects of
ATN-224 (Fig. 3C).As a control,H2O2 treatment by itself under the
conditions described above had minimal effects on the EGF-
stimulated increase in pERK in A431 cells (Fig. 3C). Similar results
were obtained when using SOD1 siRNA in A431 cells (data not
shown) and in ATN-224-treated HUVEC (Fig. S3). In contrast to
A431, H2O2 treatment of HUVEC only modestly reversed ATN-
224-mediated down-regulation of FGF-2-induced pERK. Higher
H2O2 concentrations and longer incubation times were deleterious
to HUVEC survival, precluding a clearer result. To rule out that
ATN-224 treatment was increasing peroxidase activity and causing
a reduction in H2O2 concentration, the levels of peroxiredoxins
(Prx) were evaluated in A431 cells. Prx are peroxidases that
modulate the levels ofH2O2 duringGF signaling (25, 31). The levels
of Prx II (Fig. 3D), Prx I, and 2-Cys-Prx family (data not shown)
proteins did not change significantly uponATN-224 treatment after
either 24 or 48 h. In addition, the levels of catalase and glutathione
peroxidase did not increase as determined by Western blotting in
ATN-224-treated A431 cells (data not shown). Finally, the amount
of oxidized and therefore inactive Prx increased significantly in
ATN-224-treated A431 cells as determined by Western blot, using
an antibody that is specific for the oxidized forms of Prx I to IV (Fig.
3D). These results suggest that the apparent decrease in H2O2
observed upon ATN-224 treatment was not due to an increase in
peroxidase activity. These results argue that the levels of H2O2 are
lowered in ATN-224-treated HUVEC and A431 cells, resulting in
the attenuation of the GF-stimulated MAPK pathway.
To further confirm that the effects of SOD1 inhibition in
GF-mediated MAPK signaling were due to a lack of sufficiently
high concentration of H2O2, the levels of oxidized and reduced
PTEN were measured in A431 cells exposed to H2O2. PTEN is a
well studied redox regulated lipid phosphatase (35) that, when
oxidized, forms a disulfide bond between the active site Cys residue
and a vicinal Cys residue. This alters the mobility of PTEN when
separated by SDS/PAGE (35), which makes it an ideal sensor of
changes in the redox status of proteins within the cell. A431 cells
were treated with H2O2 at 0.5 to 2 mM for 10 min to oxidize most
of the PTEN present (90% at 2 mM) (Fig. 3E). However, in
ATN-224-treated cells (5 M for 48 h), only 64% of PTEN was
oxidized at the highest H2O2 concentration (Fig. 3E), indicating
that higher levels of H2O2 were needed to oxidize and inactivate
PTEN in ATN-224-treated cells than in control cells. This is
consistent with the results presented above, which indicate de-
creased steady-state levels of H2O2 in ATN-224-treated A431 cells.
SOD1 Inhibition Protects PTP1B from H2O2-Mediated Oxidation. The
results shown in Fig. 3E also suggest that SOD1 inhibition may
result in the protection of PTPs from GF-mediated oxidation.
PTP1B, which is known to dephosphorylate the EGFR and IGF-
1R, is oxidized upon EGF or IGF-1 stimulation (24, 27). Further-
more, ATN-224 blocks EGF and IGF-1 signaling (Fig. 1), making
PTP1B a candidate PTP to be protected by SOD1 inhibition during
Fig. 2. SOD1 inhibition attenuates GF receptor phos-
phorylation. (A) A431 cells were incubated with the
indicated amounts of ATN-224 for 48 h. Then, cells were
stimulated with 100 ng/ml of EGF for 10 min and lysed
and Western blot analyses were carried out, probing for
EGFR and pEGFR (Tyr-1173). (B) A431 cells were incu-
batedwithATN-224for48h.Then, cellswere stimulated
with 100 ng/ml of EGF for 10 min and lysed and Western
blot analyses were carried out, probing for pEGFR (Tyr-
845, -992, -1045, -1068, -1086, -1148, and -1173) and
tubulin. The appropriate bands were quantitated and
normalized to tubulin. (C) HT-29 cells were incubated
with ATN-224 for 48 h. Then, cells were stimulated with
20 ng/ml of IGF-1 and lysed, and Western blot analyses
were carried out, probing for IGF-1R or pIGF-1R (Tyr-
1135/1136). (D) U87 cells were incubated with ATN-224
for 48 h in full growth media. Then, cells were lysed, and
Western blot analyses were carried out.
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GF signaling. Thus, two different methods were used to interrogate
the redox status of PTP1B in control versus ATN-224-treatedA431
cells (Fig. 4 and Fig. S4). First, using an experimental approach in
which oxidized Cys incorporate a biotin moiety, several proteins in
A431 cells (bands 1, 2, and 5) were found to be protected from
oxidation by ATN-224 (decreased signal), whereas others (bands 3,
4, 6, and 7) were not (Fig. 4A). Stimulation of A431 cells with EGF
oxidizes PTP1B, reaching a maximum after 2–5 min (Fig. S4A).
After 5 min of EGF stimulation, ATN-224 treatment protected
PTP1B from EGF-mediated oxidation in A431 cells (Fig. 4B).
Furthermore, when a maleimide-biotin reagent that selectively
reacts with free sulfhydryl groups was used, more biotin was
incorporated in the PTP1B band in ATN-224-treated A431 cells
(69 39% increase, n 3,P 0.01) than in control cells, indicating
the presence of higher levels of reduced PTP1B (Fig. S4 B and C).
Likewise, the levels of reduced PTP1B in ATN-224-treated
HUVECwere 86 50% (n 3,P 0.05) higher than control (Fig.
S4C). On the contrary, in A549, in which ATN-224 treatment does
not reduce EGF-stimulated pERK (Fig. 1D), there was no increase
in biotin incorporation (data not shown). Thus, paradoxically,
SOD1 inhibition results in antioxidant effects on PTPs likely due to
a decrease in H2O2 and prooxidant effects possibly due to an
increase in superoxide (Fig. 3 A and B and Fig. S2).
PTP Inhibitors Antagonize the Attenuation of pERK Caused by SOD1
Inhibition in GF-Stimulated Cells. Small-molecule inhibitors of PTPs
were used to confirm the hypothesis that ATN-224 effects on GF
signaling are mediated through the protection of PTPs from
oxidation. Orthovanadate is a well characterized broad spectrum
inhibitor of PTPs that has been widely used to probe the role of
PTPs in signaling (36, 37). HUVEC were treated with orthovana-
date 15 or 30 min before stimulation with FGF-2. Both orthovana-
date pretreatments abrogated the ATN-224-mediated inhibition of
ERK1/2 phosphorylation in FGF-2-treated HUVEC while having
no effect in combination with FGF-2 in control cells (Fig. 5A).
Likewise, orthovanadate pretreatment antagonized the inhibitory
effects of SOD1 siRNA on ERK1/2 phosphorylation (Fig. 5B) in
EGF-stimulatedA431 cells.Orthovanadate pretreatment increased
the levels of pERK in both SOD1 siRNA and control (Fig. 5B).
However, the change for the control siRNAwas only 21%,whereas,
for SOD1, siRNA the increase was 56% (Fig. 5B). Similar results
were obtained in repeat experiments (n  3). Consistent with the
hypothesis that PTPs, and specifically PTP1B, are a target of SOD1
inhibition, addition of a specific inhibitor of PTP1B (PTP1Bi) in
ATN-224-treated A431 cells 3 h before GF stimulation abrogated
the effects of ATN-224 on EGF-stimulated pERK (Fig. 5C). This
inhibitor has been shown to be specific for PTP1B (38). However,
it cannot be ruled out that other phosphatases were also inhibited.
Taken together, these findings suggest that SOD1 inhibition pro-
vides protection against oxidation of PTPs during GF signaling
resulting in the attenuation of ERK1/2 phosphorylation.
Discussion
Themain findings of this work are (Fig. S5) that (i) SOD1 inhibition
causes both prooxidant and antioxidant effects, (ii) excess super-
Fig. 3. ATN-224 treatment of A431 cells alters the redox state, which seems
responsible for the inhibition of ERK1/2 phosphorylation. (A) A431 cells were
incubated with ATN-224 for 48 h in full growth media. Then, cells were treated
with dihydroethidium (DHE) at 1.6M in PBS for 15 min followed by extensive
washing and analyzed by flow cytometry to determine the levels of superox-
ide (n 3; *, P 0.001). (B) A431 cells were incubated with ATN-224 for 48 h
in full growth media. Then, cytosolic aconitase activity was measured (average
ofn3 standard deviation) as described inMaterials andMethods. (C) A431
cells were incubated with 7 M ATN-224 for 48 h in full growth media. Then,
the cells were treated with 1, 10, or 100 M of H2O2 for 0.5 h in cell media
containing 0.5% FBS, washed, and then stimulated with 10 ng/ml of EGF. The
numbers under the bands [relative intensity (RI)] represent the intensity of the
pERK bands normalized to tubulin. (D) A431 cells were treated with ATN-224
for 24 or 48 h, cells were lysed, and Western blot analyses were carried out,
probing with antibodies against Prx II and Prx-SO3. The later recognizes the
oxidized forms of Prx I to IV. (E) A431 were incubated with ATN-224 for 48 h
in full growth media. Then, cells were treated with H2O2 in cell media con-
taining 0.5% FBS for 10 min. After that, cells were washed, lysed in the
presence of NEM, run on a nonreducing SDS/PAGE, transferred, and probed
with antibodies against PTEN. When PTEN is oxidized by H2O2, it runs as a
faster species than reduced PTEN in a SDS/PAGE. The numbers under the bands
(RI) represent the intensity of reduced PTEN bands normalized to tubulin.
Fig. 4. Inhibition of SOD1 by ATN-224 reduces the levels of oxidized PTP1B
and other proteins. (A) A431 cells treated with 5 M ATN-224 for 48 h were
lysed in the presence of iodoacetic acid to block reduced Cys residues, buffer
exchanged, reduced with DTT and reacted with maleimide-biotin so that
originally oxidized proteins would acquire a biotin label. Proteins were then
IP with streptavidin–agarose (SA) followed by Western blot analysis, which
was probed for biotin. (B) A431 cells were treated with 5M ATN-224 for 48 h
and then stimulated with 100 ng/ml of EGF for 5 min and treated as in B, and
biotinylated proteins were then immunoprecipitated with SA followed by
Western blot analysis, which was probed for PTP1B.
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oxide does not oxidize PTP1B, and (iii) SOD1 plays an essential
role in GF-mediated MAPK signaling by mediating the transient
oxidation and inactivation of PTPs. These conclusions are drawn
from studies performed with several tumor cell lines, primary
endothelial cells and fibroblasts. In A549 cells, SOD1 inhibition did
not attenuate GF signaling. This cell line contains a mutated
constitutively active formofRas that is known to regulateROS (26)
and, as such, may overcome the effects of SOD1 inhibition.
Moreover, mutated Ras constitutively activates the MAPK path-
way, which may also oppose the effects of SOD1 inhibition of ERK
phosphorylation. Finally, it is presently unclear how ATN-224
treatment down-regulates the levels of the PDGF receptor in U87
cells (Fig. 2D).
Although the type and origin of ROS that inactivates PTPs
during GF signaling has not been unequivocally identified, it is
generally accepted that GF binding to its receptor increases levels
of superoxide, which is then dismutated into H2O2 (22, 23, 26).
Because superoxide can dismutate non-enzymatically at a fast rate
(5 105 M1s1) (12, 14) and because superoxide can potentially
oxidize PTPs (39), the possible contribution of SOD1 to this
process has been neglected. However, the results presented here
demonstrate that superoxide does not oxidize PTP1B and that the
spontaneous dismutation of superoxide is insufficient to generate
the levels of H2O2 needed for PTP inactivation. Therefore, enzy-
matically active SOD1 is required for PTP oxidation during GF
signaling. Our results show that SOD1 inhibition protects PTP1B
from oxidation in A431 cells and HUVEC. This protection oc-
curred under basal conditions (Fig. S4) and immediately after EGF
stimulation (Fig. 4B). Furthermore, the effects of SOD1 inactiva-
tion on ERK phosphorylation were dependent on having active
PTPs. This was demonstrated by reversing the effects of ATN-224
or SOD1 siRNA on GF-stimulated ERK1/2 phosphorylation by
two different approaches: by adding H2O2 exogenously, which
should oxidize and inactivate PTPs, and by treating with two
different PTP inhibitors, orthovanadate and a specific PTP1B
inhibitor. PTP1B is known to dephosphorylate EGFR and IGF-1R
(24, 27, 28), which are also targets for SOD1 inhibition in A431 and
HT-29 cells. Therefore, PTP1B was a candidate PTP responsible
for the SOD1-mediated effects on the GF-stimulated MAPK
pathway. We demonstrated (Fig. 5C) that a pharmacological in-
hibitor of PTP1B blocked the effects of ATN-224 on ERK phos-
phorylation in response to EGF stimulation. Although it cannot be
ruled out that the PTP1B inhibitor cross-reacted with other PTPs,
this result suggested an important role for PTP1B as an effector of
SOD1 inhibition, which is in agreement with the partial inhibition
observed at the level of the GF tyrosine kinase receptor by
ATN-224 treatment (Fig. 2 A–C). Consistent with this hypothesis,
a number of unidentified redox regulated proteins, some of which
could be PTPs, were also protected from oxidation during GF
stimulation by SOD1 inhibition (Fig. 4A). Other possible PTPs that
are affected by SOD1 inhibition must still be identified.
As we have shown in Fig. 3E, the levels of oxidized and inactive
Prx increased upon ATN-224-mediated SOD1 inhibition poten-
tially due to the excess superoxide generated. This result raises the
possibility that the reversible inactivation of Prx that occurs during
GF signaling (25, 31), allowing the accumulation of sufficiently high
H2O2 concentrations, may be initiated by superoxide. SOD1 inhi-
bition increased the steady-state levels of superoxide considerably
as determined by direct measurements of superoxide, using the
superoxide sensitive fluorescent dye DHE and other methods.
Superoxide is short lived and reactive but did not spontaneously
convert into H2O2 to any appreciable level, as previously discussed.
Instead, the excess superoxide was involved in other reactions, such
as with Prx and aconitase. The increase in the level of superoxide
that occurs after a 50% inhibition in the activity of SOD1 inactivates
15–30% of total aconitase (32). At 500 nM ATN-224, a 50%
inhibition of cytosolic aconitase activity in A431 cells was observed
(Fig. 3B), suggesting that significantly high levels of superoxide are
generated at those concentrations of ATN-224. Besides aconitase
and Prx, our results show that superoxide reacted with a number of
unidentified proteins, determined by measuring total protein car-
bonylation in ATN-224-treated A431 cells. Thus, these reactions
account at least partially for the excess superoxide. Surprisingly,
superoxide cannot oxidize PTP1B in vivo, but it does so in vitrowith
high efficiency (39). This suggests that either competing reactions
scavenge superoxide very efficiently or that some type of compart-
mentalization prevents superoxide from reaching PTP1B, or both.
The data presented here indicate that SOD1 is essential for
GF-mediated ERK1/2 phosphorylation. It is unclear although how
this inhibition contributes to the antiproliferative activity of ATN-
224, because partial SOD1 inhibition with siRNA did not have an
effect on proliferation butwas sufficient to inhibit pERKuponEGF
stimulation in A431 cells. It is reasonable to hypothesize that SOD1
inhibition will also affect other signaling pathways that are regu-
lated by H2O2. Finally, the data presented here support the hy-
pothesis that SOD1 is a therapeutic target for the treatment of
cancer and that inhibiting SOD1 results in the down-regulation of
Fig. 5. PTP inhibitors block ATN-224 and SOD1 siRNA-mediated attenuation of
ERK1/2 phosphorylation. (A) HUVEC were incubated with ATN-224 for 48 h in full
growth media. Cells were then treated with orthovanadate for either 15 or 30
min followed by stimulation with FGF-2 and lysed, and Western blot analyses
were carried out. The numbers under the bands (relative intensity) represent the
intensity of the pERK bands normalized to tubulin. (B) A431 cells were treated
eitherwith7MATN-224(224)for48hortransfectedwithSOD1siRNAorcontrol
siRNA for 48 h. Cells were then treated with 1 mM orthovanadate (V) for 15 min
or not treated before stimulation with 10 ng/ml of EGF for 10 min. Cells were
lysed, and Western blot analyses were carried out. V, orthovanadate treatment;
224, ATN-224 treatment. (C) A431 cells were treated with ATN-224 for 48 h and
exposed to a PTP1B inhibitor 1 h before being stimulated with 10 ng/ml of EGF for
10 min. Cells were lysed, and ELISAs were carried out, probing for ERK1/2, pERK.
The graph shows means SD (n 3) of pERK normalized to ERK1/2.
Juarez et al. PNAS  May 20, 2008  vol. 105  no. 20  7151
BI
O
CH
EM
IS
TR
Y
multiple signaling pathways important for endothelial and tumor
cell function.
Materials and Methods
Cells and Antibodies.A431, HT-29, A549, and U87 were obtained from American
Type Culture Collection (ATCC), and HUVEC and HDFa were from Cascade Bio-
logics. FGF-2, EGF, IGF-1 and PDGF were from R&D Systems. ATN-224 (choline
tetrathiomolybdate) was manufactured under cGMP, using a proprietary man-
ufacturing process. The antibodies against ERK1/2, pERK1/2, EGF, pEGF (Tyr 845,
992, 1045, 1068, 1148, and 1173), IGF-1R, pIGF-1R (Tyr 1135/1136), cleaved
PARP, and PTEN were from Cell Signaling. Antibodies against pEGFR (Tyr 1086),
Prx I, PrxII, Prx-2Cys, and Prx-SO3 were from Abcam. The antibody against PDGFR
was from Upstate Biotechnology. The antibody against -tubulin was from
Santa Cruz Biotechnology, and the antibody against SOD1 was from Biodesign
International.
SOD Activity and MTT Assay. SOD activity and MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assays were performed as described in ref. 1.
Western Blot Analysis and Immunoprecipitations. Cells were plated in full
growth media containing 10% FBS and incubated in ATN-224. Cells were then
stimulated with the proper growth factor in the presence of 0.5% FBS media,
harvested, and lysed in RIPA [1% Nonidet P-40, 0.25% sodium deoxycholate, 150
mM NaCl, and 50 mM Tris (pH 7.4)] with protease inhibitors (Roche), 1 mM AEBSF
(Calbiochem), and phosphatase inhibitors Set I and II (Calbiochem). Lysates were
subjected to Western blot analysis, using an antibody specific with appropriate
loading controls. Bands were quantitated using a Kodak Image Station 400.
Immunoprecipitations were carried out by using 200–500 g of cell extract
incubated overnight with 20 l of a protein G–agarose slurry (Roche) or strepta-
vidin–agarose (Pierce).
SOD siRNA Transfection Experiments. SOD1 Stealth siRNA (Invitrogen) or me-
dium GC% Negative control siRNA (Invitrogen; catalog no. 12935-300) was di-
luted with OptiMEM I (Invitrogen). Lipofectamine RNAiMAX (Invitrogen) was
diluted 1:100 with siRNA and incubated for 0.5 h at ambient temperature. A431
cells were plated at 100,000 cells per well in a 12-well plate containing siRNA/
RNAiMAX solution. After overnight incubation, the media was replaced with
10% FBS DMEM  7 M ATN-224 and incubated for another 48 h. Cells were
stimulated with 0.5% FBS and DMEM 100 ng/ml EGF for 10 min. Extracts were
prepared with RIPA, 1 mM AEBSF, and phosphatase inhibitors Set I and II
(Calbiochem).
Aconitase assay. Aconitase was assayed according to the manufacturer’s proto-
col (OXIS International), using a 96-well assay plate in a SpectraMax plate reader.
Detection of Superoxide or H2O2. A431 cells were incubated with the indicated
amounts of ATN-224 for 48 h. Cells were then trypsinized, washed with PBS,
counted, and resuspended in PBS. For superoxide measurements, dihydro-
ethidium (DHE) (Invitrogen) was added to the cells at 1.6M for 15 min. For H2O2
measurements, H2DCFDA (Invitrogen) at 20M was added to the cells for 15 min.
After incubation with the respective dyes, the cells were extensively washed and
analyzed by flow cytometry.
Determination of Redox Status of PTP. To determine the redox status of PTEN,
A431 cells that had been treated with ATN-224 for 48 h were exposed to
increasing concentrations of H2O2 for 10 min, lysed in the presence of N-
ethylmaleimide (NEM), and analyzed by western blot with an antibody against
PTEN. To determine the redox status of PTP1B, A431 cells were treated for 48 h
with ATN-224 and lysed after treatment with EGF. The lysis buffer was degassed,
supplemented with freshly prepared iodoacetic acid (10 mM), catalase (100
g/ml), and superoxide dismutase (100g/ml) and placed on ice. Cell plates were
moved into an anaerobic chamber and rapidly lysed. Alkylation of free thiols was
allowed to occur for a 1 h. Cell lysate was then applied to desalting columns
(Pierce) containing 1 mM DTT to allow reversibly oxidized PTPs to be reduced
back. Samples were centrifuged, and the eluate was incubated with a biotin-
conjugated PEO-iodoacetyl probe (5 mM) (Pierce) for 1 h. Biotinylated proteins
were purified by streptavidin–Sepharose pulldown, and Western blot analysis
was carried out by probing with a PTP1B antibody or streptavidin–HRP.
Statistical Analysis. GraphPad software was used for all statistical analysis. Data
are presented as mean SD. Data were analyzed by using unpaired, two-tailed
t tests when comparing two variables.
Supporting Information. Apoptosis studies, protein carbonylation, and the de-
termination of redox status of PTP1B are described in SI Materials andMethods.
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